Placing the Allergen Tablet Under the Tongue
Placeholder: a fast-dissolving tablet is tucked under the tongue daily.
- Daily: Dosing frequency (Placeholder: once-daily home dosing.)
- ~2 min: Hold time (Placeholder: tablet held before swallowing.)
- Grass, dust, ragweed: Allergen types (Placeholder: common extract targets.)
- Clinic-observed: First dose setting (Placeholder: first dose under supervision.)
Why sublingual placement
Placeholder: sublingual site chosen for rich vascularity and easy access.
Extract Absorption Through Sublingual Mucosa
Placeholder: dissolved allergen diffuses through thin sublingual tissue.
- Thin: Mucosa thickness (Placeholder: favors rapid extract diffusion.)
- <3 min: Dissolve time (Placeholder: tablet fully dissolves quickly.)
- High: Blood supply (Placeholder: sublingual area is highly vascular.)
- Low: Systemic exposure (Placeholder: limited compared to injections.)
Absorption pathway
Placeholder: extract passes epithelium into local immune tissue.
Dendritic Cells Sample Antigen Tolerogenically
Placeholder: local dendritic cells capture antigen and induce tolerance.
- Dendritic cells: Cell type (Placeholder: oral mucosa resident antigen cells.)
- Tolerogenic: Response bias (Placeholder: favors regulatory T-cell induction.)
- IL-10 / TGF-β: Key cytokine (Placeholder: regulatory signaling molecules.)
- Hours: Time to signal (Placeholder: sampling begins within hours.)
Tolerance induction mechanism
Placeholder: regulatory T-cells expand, dampening allergic response.
Self-Administration Convenience at Home
Placeholder: patients dose themselves without repeated clinic visits.
- 1–2: Clinic visits/yr (Placeholder: far fewer than injection therapy.)
- None: Needle use (Placeholder: no injections required at home.)
- Moderate: Adherence challenge (Placeholder: daily habit needed for years.)
- Room temp: Storage (Placeholder: tablets stored without refrigeration.)
Convenience trade-offs
Placeholder: convenience depends on sustained daily adherence.
SLIT Tablets vs Subcutaneous Injection Immunotherapy
Placeholder: multi-year SLIT trials show efficacy near SCIT injections.
- Comparable: Symptom relief (Placeholder: similar long-term symptom scores.)
- Lower: Systemic reaction risk (Placeholder: fewer severe reactions than injections.)
- 3 years: Course length (Placeholder: typical recommended treatment duration.)
- Rare: Anaphylaxis risk (Placeholder: lower than subcutaneous route.)
Choosing between routes
Placeholder: SLIT trades clinic-based potency for home convenience.
Placeholder: both routes can achieve durable allergen tolerance.